TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01489826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.
Study: NCT03049397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Complete Enhancing Connections program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03539198

Intervention type: RADIATION
Intervention: Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)
Description: Patients will be receiving proton SBRT

Intervention type: RADIATION
Intervention: Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).
Description: Patients will receive proton SBRT.

Intervention type: DRUG
Intervention: Nivolumab 3 mg/kg IV q2 weeks
Description: Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.

Intervention type: DRUG
Intervention: Nivolumab 3 mg/kg IV q2 weeks
Description: Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.

Intervention type: RADIATION
Intervention: Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).
Description: Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.

Intervention type: RADIATION
Intervention: Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).
Description: Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
Study: NCT03432039

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
Study: NCT02622139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: MSOT for the evaluation of disease activity in IBD patients
Study: NCT04374617

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound and Computed Tomography Angiography
Description: All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
Study: NCT01899495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sodium diet and low sodium diet
Description: Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
Study: NCT02062190

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol
Description: 100mg 2x/day~1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: 100mg 2x/day~1 month
Study: NCT00633867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath
Description: Tracheal intubation, using Mcgrath video-laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using Macintosh Laryngoscope
Description: Tracheal intubation using Macintosh Laryngoscope
Study: NCT05313919

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive functional diagnostics of coronary circulation
Description: Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive functional diagnostics of coronary circulation
Description: Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines
Study: NCT02615925

Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatry Consultation
Description: Psychiatry Consultation
Study: NCT03486704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to Face VRRS and telerehabilitation
Description: Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation program
Description: The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTF VRRS plus unstructured CS
Description: Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to Face VRRS plus active tDCS and telerehabilitation
Description: Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face VRRS plus placebo tDCS and telerehabilitation
Description: Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).
Study: NCT04276454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus system
Description: A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
Study: NCT03714737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: experimental vaccine
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: experimental vaccine
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: experimental vaccine
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: experimental vaccine
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: experimental vaccine
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control vaccine 1
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control vaccine 1
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control vaccine 2
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control vaccine 2
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
Study: NCT02845518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (cMRI)
Description: Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9.
Study: NCT03499600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Assessment and CFI
Description: CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Assessment
Description: CA families will participate their standard intake procedures.
Study: NCT02914106

Intervention type: OTHER
Intervention: Observational Study
Description: Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.

Intervention type: OTHER
Intervention: Observational Study
Description: Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
Study: NCT05661760

Intervention type: BEHAVIORAL
Intervention: interdisciplinary multimodal pain treatment
Description: A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
Study: NCT02367040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
Study: NCT01534403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
Study: NCT00527748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Measuring Ankle Exerciser
Description: Stretching exercise performed 10 times per day, for six (6) weeks.
Study: NCT03048019

Intervention type: DRUG
Intervention: Tirofiban
Description: Patients will receive Tirofiban during the PCI procedure

Intervention type: DRUG
Intervention: Cangrelor
Description: Patients will receive Cangrelor during the PCI procedure
Study: NCT01974687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to uprifosbuvir capsule administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to uprifosbuvir capsule administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
Study: NCT02868710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
Study: NCT04282811

Intervention type: DRUG
Intervention: Venetoclax
Description: Patients treated with venetoclax-based regimens outside clinical trials in Italy
Study: NCT01641666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b 1.5 mcg/kg/week
Description: Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
Study: NCT04086134

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fruit Products
Description: Fruit Products with the potential to improve constipation-related outcomes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Products
Description: Fruit Products with the potential to improve constipation-related outcomes
Study: NCT03240055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: etomidate
Description: receive etomidate only